1.95
+0.04(+2.09%)
Currency In
| Previous Close | 1.91 |
| Open | 1.92 |
| Day High | 1.98 |
| Day Low | 1.92 |
| 52-Week High | 21 |
| 52-Week Low | 1.81 |
| Volume | 200,072 |
| Average Volume | 3.08M |
| Market Cap | 315.04M |
| PE | -1.59 |
| EPS | -1.23 |
| Moving Average 50 Days | 6.88 |
| Moving Average 200 Days | 10.24 |
| Change | 0.04 |
If you invested 1000 in Neumora Therapeutics, Inc. Common Stock (NMRA) since IPO date, it would be worth 120 as of February 05, 2025 at a share price of 1.95. Whereas If you bought 1000 worth of Neumora Therapeutics, Inc. Common Stock (NMRA) shares 1 year ago, it would be worth 128.46 as of February 05, 2025 at a share price of 1.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
GlobeNewswire Inc.
Jan 02, 2025 12:00 PM GMT
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an efficacy signal in female participants; Company plans t
Neumora Therapeutics to Participate in Upcoming Conferences in November
GlobeNewswire Inc.
Nov 06, 2024 12:00 PM GMT
WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today annou
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
GlobeNewswire Inc.
Oct 29, 2024 11:00 AM GMT
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today annou